About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site   |  How to Help!

Patients Against Lymphoma

 

Treatments > Time to Progression Table

Last update: 04/24/2010

Table Showing Median Time-to-Progression Following Initial Treatment 
for Indolent Follicular and Related B-cell Lymphomas

 

Treatment
Patient Class
Time-to-Progression
Response
Rate 
Reference | Dates
Prednimustine vs. CVP (COP)
246 pt - low grade with 10% high grade
31 vs. 14 mo.
 
Semin. Oncol., 1986;1 (suppl 1) 19-22 1986 abstract
CVP (COP) vs. Prednimustine/mixoxantrone
344/442 symptomatic follicular 
14 vs. 31 mo.
 
Leukemia, 1996; 10: 836-43
CVP vs. Fludara
303/381 NHL Working formulation class ABC, CLL excluded
15 vs. 21 mo.
 
ASH 2001, Abstract 3501 Abstract
CHOP vs. 
CHOP plus interferon
 
1.9 vs. 2.9 yrs
 
Blood, 1998; 92 (Suppl 1): 486
CHOP-B
B = 
       
Alternating CHOP/FMD 
87 NHLpts bulky
29 mo.
95% (79 CR in 83 evaluable pts.
Clin Lymphoma 2002 Mar;2(4):229-37 abstract
Other Studies presenting median Time to Progression
Vaccine responders vs. non-responders/ historical controls
 follicular NHL 
7.9 vs. 1.3 yrs (initial report)
 
>10 yrs vs. 1.3 yrs (last report)
 
J.Timmerman & R.Levy, Clinical Lymphoma 1(2), 129-139 (2000).
Vaccine vs. Antibody/Toxin (PACE Chemotherapy)
 
90% disease free at 3 yrs 
vs.  50% at 2.2 yrs after PACE
 
1999
Not specified
Indolent, bcl2 positive
PCR-negative 73% 5 yr FFS 
vs. PCR positive 28%
 
Ann Oncol 2000;11 Suppl 1:137-40
Fludarabine Mitoxantrone
8 Follicular 
/11 CLL/SLL
15 mo
 
Hematol Oncol 1998 Sep;16(3):107-16
ProMacc+Mopp plus Radiation
Various
> 48 mo
 
Semin Hematol 1988 Apr;25(2 Suppl 2):11-6
FLU vs. FLU-ID(Idarubicine)
Mixed types
62% vs. 84% remained in remission at 19 mo.
 
J Clin Oncol 2000 Feb;18(4):773-9
1995-1998
Fludarabine/ Mitoxantrone/ Dexamethasone Alternating with CHOP
87
83 evaluable
follicular, bulky
 29 mo.
95%
Clin Lymphoma 2002 Mar;2(4):229-37
Studies including Monoclonal Antibodies
CHOP plus Rituxan 

Also see, PubMed: related articles
38
82.3  mo. Median duration  (ASH 2003)  

..." responses were durable with a progression-free survival and median duration of response >5 years." PMID: 12662126
100%, 63% - CR
J Clin Oncol 1999 Jan;17(1):268-76
ASH 2001, 2519 

Drugs. 2003;63(8):803-43.  
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Fludara plus Rituxan
36
14+ mo. Median duration not reached
 
ASH 2001, 2518
Rituxan +  interferon-alpha-2a
38
relapsed or refractory, lg follicular, NHL
25.2 mo. in responders
45%  -  11% - CR, 34% - PR
Clin Cancer Res 2000 Jul;6(7):2644-52 abstract
CR - Complete response
PR - Partial response (50% regression or better) 
ORR  - Overall Response Rate
Time to Progression is considered by the FDA to be a surrogate marker that might infer (but does not prove) improved survival.  
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright 2004,  All Rights Reserved.